Cargando…
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment w...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747480/ https://www.ncbi.nlm.nih.gov/pubmed/26894205 http://dx.doi.org/10.1212/NXI.0000000000000202 |
_version_ | 1782414985409855488 |
---|---|
author | Hegen, Harald Adrianto, Indra Lessard, Christopher J. Millonig, Alban Bertolotto, Antonio Comabella, Manuel Giovannoni, Gavin Guger, Michael Hoelzl, Martina Khalil, Michael Fazekas, Franz Killestein, Joep Lindberg, Raija L.P. Malucchi, Simona Mehling, Matthias Montalban, Xavier Rudzki, Dagmar Schautzer, Franz Sellebjerg, Finn Sorensen, Per Soelberg Deisenhammer, Florian Steinman, Lawrence Axtell, Robert C. |
author_facet | Hegen, Harald Adrianto, Indra Lessard, Christopher J. Millonig, Alban Bertolotto, Antonio Comabella, Manuel Giovannoni, Gavin Guger, Michael Hoelzl, Martina Khalil, Michael Fazekas, Franz Killestein, Joep Lindberg, Raija L.P. Malucchi, Simona Mehling, Matthias Montalban, Xavier Rudzki, Dagmar Schautzer, Franz Sellebjerg, Finn Sorensen, Per Soelberg Deisenhammer, Florian Steinman, Lawrence Axtell, Robert C. |
author_sort | Hegen, Harald |
collection | PubMed |
description | OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment were included in this prospective, observational study. Number of relapses and changes in disability were assessed 2 years prior to and 2 years after initiation of treatment. Sera were collected at baseline and after 3 months on therapy. Cytokine levels in sera were assessed by Luminex multiplex assays. Baseline cytokine profiles were grouped by hierarchical clustering analysis. Demographic features, changes in cytokines, and clinical outcome were then assessed in the clustered patient groups. RESULTS: A total of 157 patients were included in the study and clustered into 6 distinct subsets by baseline cytokine profiles. These subsets differed significantly in their clinical and biological response to IFN-β therapy. Two subsets were associated with patients who responded poorly to therapy. Two other subsets, associated with a good response to therapy, showed a significant reduction in relapse rates and no worsening of disability. Each subset also had differential changes in cytokine levels after 3 months of IFN-β treatment. CONCLUSIONS: There is heterogeneity in the immunologic pathways of the RRMS population, which correlates with IFN-β response. |
format | Online Article Text |
id | pubmed-4747480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-47474802016-02-18 Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients Hegen, Harald Adrianto, Indra Lessard, Christopher J. Millonig, Alban Bertolotto, Antonio Comabella, Manuel Giovannoni, Gavin Guger, Michael Hoelzl, Martina Khalil, Michael Fazekas, Franz Killestein, Joep Lindberg, Raija L.P. Malucchi, Simona Mehling, Matthias Montalban, Xavier Rudzki, Dagmar Schautzer, Franz Sellebjerg, Finn Sorensen, Per Soelberg Deisenhammer, Florian Steinman, Lawrence Axtell, Robert C. Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To evaluate serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)–β treatment in patients with multiple sclerosis (MS). METHODS: Patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome receiving de novo IFN-β treatment were included in this prospective, observational study. Number of relapses and changes in disability were assessed 2 years prior to and 2 years after initiation of treatment. Sera were collected at baseline and after 3 months on therapy. Cytokine levels in sera were assessed by Luminex multiplex assays. Baseline cytokine profiles were grouped by hierarchical clustering analysis. Demographic features, changes in cytokines, and clinical outcome were then assessed in the clustered patient groups. RESULTS: A total of 157 patients were included in the study and clustered into 6 distinct subsets by baseline cytokine profiles. These subsets differed significantly in their clinical and biological response to IFN-β therapy. Two subsets were associated with patients who responded poorly to therapy. Two other subsets, associated with a good response to therapy, showed a significant reduction in relapse rates and no worsening of disability. Each subset also had differential changes in cytokine levels after 3 months of IFN-β treatment. CONCLUSIONS: There is heterogeneity in the immunologic pathways of the RRMS population, which correlates with IFN-β response. Lippincott Williams & Wilkins 2016-01-27 /pmc/articles/PMC4747480/ /pubmed/26894205 http://dx.doi.org/10.1212/NXI.0000000000000202 Text en © 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Article Hegen, Harald Adrianto, Indra Lessard, Christopher J. Millonig, Alban Bertolotto, Antonio Comabella, Manuel Giovannoni, Gavin Guger, Michael Hoelzl, Martina Khalil, Michael Fazekas, Franz Killestein, Joep Lindberg, Raija L.P. Malucchi, Simona Mehling, Matthias Montalban, Xavier Rudzki, Dagmar Schautzer, Franz Sellebjerg, Finn Sorensen, Per Soelberg Deisenhammer, Florian Steinman, Lawrence Axtell, Robert C. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title | Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title_full | Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title_fullStr | Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title_full_unstemmed | Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title_short | Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
title_sort | cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747480/ https://www.ncbi.nlm.nih.gov/pubmed/26894205 http://dx.doi.org/10.1212/NXI.0000000000000202 |
work_keys_str_mv | AT hegenharald cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT adriantoindra cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT lessardchristopherj cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT millonigalban cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT bertolottoantonio cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT comabellamanuel cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT giovannonigavin cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT gugermichael cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT hoelzlmartina cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT khalilmichael cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT fazekasfranz cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT killesteinjoep cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT lindbergraijalp cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT malucchisimona cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT mehlingmatthias cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT montalbanxavier cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT rudzkidagmar cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT schautzerfranz cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT sellebjergfinn cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT sorensenpersoelberg cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT deisenhammerflorian cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT steinmanlawrence cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients AT axtellrobertc cytokineprofilesshowheterogeneityofinterferonbresponseinmultiplesclerosispatients |